2020 ttf alk session raez sequence of alk inhibitors
Published 3 years ago • 66 plays • Length 23:44Download video MP4
Download video MP3
Similar videos
-
3:06
2020 ttf alk session qa panel progression on 2nd-gen alk inhibitor if biopsy shows no alk mutation
-
25:07
2020 ttf alk session - lin - tkis for ros1
-
3:46
2020 ttf alk session qa panel the use of an alk tki post chemoradiation for stage 3b lung cancer
-
1:50
2020 ttf alk/ros session qa panel the difference in efficacy of tkis in different patients
-
2:16
2020 ttf alk session qa panel ros1 patients on immunotherapy chemotherapy combinations
-
2:36
2020 ttf alk session qa panel information on the crown trial and firstline lorlatinib
-
1:43
2020 ttf alk session qa panel reducing dosage on lorlatinib vs switching to a different agent
-
4:20
video 2020 ttf alk/ros session qa panel the efficacy of dose reduction or interruption of crizotinib
-
2:16
2020 ttf alk session qa panel using ctc profiling to detect crizotinib resistance on progression
-
2:34
2020 ttf alk session qa panel next steps after progression on lorlatinib
-
1:47
alk rearrangements: what are they, and who has them?
-
9:59
case based panel discussions - alk positive, developing resistance to alk inhibitors and next steps
-
1:57
video 2020 ttf alk/ros session qa panel ros1 patients - chemo after resistance to inhibitor therapy?
-
26:56
gracecast-085_lung-cancer_alk inhibition: who to screen and options for alk-positive patients
-
4:08
2020 ttf alk/ros session qa panel treatment decisions for simultaneous egfr and ros1 mutation
-
3:24
2020 ttf alk qa panel ros1 clinical trial updates
-
2:20
timing of second generation alk inhibitors: first line vs. treatment after acquired resistance
-
19:31
2020 ttf am session - janne - insights into acquired resistance: the role of repeat biopsies
-
1:57
alk nsclc: what does it mean? - 2022 program: targeted therapies forum